announced the decision to discontinue the development of Danuglipron (PF-06882961), an oral GLP-1 receptor agonist previously investigated for chronic weight management
Srivastava G, Fox CK, Kelly AS, Jastreboff AM, Browne AF, Browne NT, et al
originated from China
The injection timing is flexible, not linked to meals
While clinical data remains important, it is no longer enough on its own
Hohenfellner K, Rauch F, Ariceta G, Awan A, Bacchetta J, Bergmann C, Bechtold S, Cassidy N, Deschenes G, Elenberg E, Gahl WA, Greil O, Harms E, Herzig N, Hoppe B, Koeppl C, Lewis MA, Levtchenko E, Nesterova G, Santos F, Schlingmann KP, Servais A, Soliman NA, Steidle G, Sweeney C, Treikauskas U, Topaloglu R, Tsygin A, Veys K, R VV, Zustin J, Haffner D (2019) Management of bone disease in cystinosis: statement from an international conference